Abilify aripiprazole regulatory update

FDA approved ANDAs from multiple companies for generic versions of Otsuka’s Abilify aripiprazole to treat schizophrenia and bipolar disorder. Abilify is a small molecule partial agonist of the dopamine D2 and serotonin (5-HT1A) receptors and antagonist of the serotonin (5-HT2A) receptor. ...